Introduction
Colorectal cancer is one of the common malignant tumors, which usually occurs in the mucosal cells of the large intestine or rectum. Currently, the main treatments for colorectal cancer include surgical resection, chemotherapy, radiotherapy, and targeted therapy. Surgical resection is the main treatment method for early-stage colorectal cancer, especially for locally restricted tumors. However, advanced colorectal cancer may require adjuvant chemotherapy or radiotherapy to reduce tumor size or control metastasis. In recent years, targeted therapy has gradually become part of the treatment strategy, and specific molecular targets are inhibited to curb the growth and spread of tumors. Among patients who use current therapies to treat colorectal cancer, 30-40% of patients experience recurrence after surgical resection, and 50% of colorectal cancer patients develop liver and lung metastases, resulting in at least two-thirds of colorectal cancer deaths.
This patent uses a pharmaceutical kit composed of a midostaurin compound combined with an anti-PD-1 antibody or an anti-PD-L1 antibody, which should be used to treat colorectal cancer. This case provides an improvement on the existing method of treating colorectal cancer, using midostaurin, or using it in combination with anti-PD-1 antibodies, to improve the anti-tumor immune response, thereby achieving the efficacy of treating colorectal cancer.
Features / strengths
1. Propose new combinations of anti-cancer treatments.
2. Propose the concept of new uses of old drugs and discover new target treatments (new indication)
3. The therapeutic effect of this new anti-cancer treatment combination is better than that of individual treatments, and it has an additive effect.
Specification in detail
Under development
Seek of partners for business cooperation
